Morgan Stanley
IDYA icon

Morgan Stanley’s IDEAYA Biosciences IDYA Stock Holding History

Morgan Stanley’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72M Buy
1,931,491
+71,038
+4% +$2.17M ﹤0.01% 1858
2026
Q1 		$62M Buy
1,860,453
+608,049
+49% +$20.4M ﹤0.01% 1876
2025
Q4 		$43.3M Sell
1,252,404
-327,949
-21% -$10.5M ﹤0.01% 2222
2025
Q3 		$43M Buy
1,580,353
+126,976
+9% +$3.07M ﹤0.01% 2140
2025
Q2 		$30.5M Sell
1,453,377
-233,211
-14% -$4.47M ﹤0.01% 2398
2025
Q1 		$27.6M Buy
1,686,588
+131,508
+8% +$2.8M ﹤0.01% 2359
2024
Q4 		$40M Buy
1,555,080
+1,194,443
+331% +$33.8M ﹤0.01% 2046
2024
Q3 		$11.4M Sell
360,637
-423,488
-54% -$16.1M ﹤0.01% 3327
2024
Q2 		$27.5M Buy
784,125
+20,507
+3% +$812K ﹤0.01% 2325
2024
Q1 		$33.5M Sell
763,618
-469,653
-38% -$20.2M ﹤0.01% 2139
2023
Q4 		$43.9M Buy
1,233,271
+1,000,495
+430% +$29.9M ﹤0.01% 1859
2023
Q3 		$6.28M Sell
232,776
-119,790
-34% -$3.04M ﹤0.01% 3551
2023
Q2 		$8.29M Buy
352,566
+261,814
+288% +$5.38M ﹤0.01% 3342
2023
Q1 		$1.25M Buy
90,752
+32,635
+56% +$544K ﹤0.01% 4734
2022
Q4 		$1.06M Buy
58,117
+9,085
+19% +$153K ﹤0.01% 4840
2022
Q3 		$732K Sell
49,032
-37,023
-43% -$481K ﹤0.01% 5067
2022
Q2 		$1.19M Sell
86,055
-34,784
-29% -$387K ﹤0.01% 4911
2022
Q1 		$1.35M Buy
120,839
+81,646
+208% +$1.2M ﹤0.01% 4785
2021
Q4 		$926K Buy
39,193
+11,810
+43% +$274K ﹤0.01% 5130
2021
Q3 		$698K Buy
27,383
+15,825
+137% +$370K ﹤0.01% 5302
2021
Q2 		$243K Buy
11,558
+11,327
+4,903% +$233K ﹤0.01% 5914
2021
Q1 		$6K Sell
231
-11,719
-98% -$226K ﹤0.01% 7059
2020
Q4 		$167K Buy
11,950
+7,341
+159% +$99.5K ﹤0.01% 5678
2020
Q3 		$58K Sell
4,609
-2,107
-31% -$26.1K ﹤0.01% 5673
2020
Q2 		$96K Buy
6,716
+6,192
+1,182% +$48.8K ﹤0.01% 5418
2020
Q1 		$2K Sell
524
-376
-42% -$2.66K ﹤0.01% 6385
2019
Q4 		$7K Buy
+900
New +$6.42K ﹤0.01% 6344

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Morgan Stanley's IDYA Position: Q2 2026 in Review

Morgan Stanley increased its IDEAYA Biosciences (IDYA) stake by 3.8% in Q2 2026, buying an estimated $2.17M and bringing the position to 1,931,491 shares worth $72M. The position accounts for ﹤0.01% of the portfolio, ranked #1858.

Morgan Stanley first reported a position in IDYA in Q4 2019 and has held it in 27 quarters since. 284 funds tracked by Wall St. Rank hold IDYA as of Q2 2026.

  • Morgan Stanley held 1,931,491 shares of IDEAYA Biosciences worth $72M as of Q2 2026.
  • Morgan Stanley bought 71,038 IDEAYA Biosciences shares in Q2 2026, an estimated $2.17M.
  • IDEAYA Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #1858 holding.
  • Morgan Stanley first reported a position in IDEAYA Biosciences in Q4 2019 and has held it in 27 quarters since.
  • 284 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.